Related Experiment Video
Updated: Jul 15, 2026
06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet's disease
Lothar Krause1, Andreas Altenburg, Nikolaos E Bechrakis
1Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany. lothar.krause@charite.de
Summary
Interferon-alpha combined with intraocular surgery significantly improved vision in Adamantiades-Behçet's disease patients. This treatment approach reduced inflammation and recurrence, offering a safe option for ocular complications.
Area of Science:
- Ophthalmology
- Rheumatology
- Immunology
Background:
- Adamantiades-Behçet's disease (ABD) is a multisystem disorder characterized by recurrent ulcerations and potential ocular involvement.
- Ocular manifestations significantly impact patient quality of life and can lead to blindness if untreated.
- Intraocular surgery is sometimes necessary for complications like retinal detachment, glaucoma, or cataracts in ABD patients.
Purpose of the Study:
- To evaluate the efficacy and safety of intraocular surgery combined with systemic interferon-alpha treatment in patients with ocular Adamantiades-Behçet's disease.
- To assess the rate of intra- and peri-operative inflammation recurrence after surgery in this patient cohort.
Main Methods:
- A prospective study involving five patients (eight eyes) with ocular ABD undergoing intraocular surgery (vitrectomy, phacoemulsification, trabeculectomy) between 1999 and 2005.
- All patients received systemic treatment with interferon-alpha.
- Mean follow-up duration was 49 months.
Main Results:
- Seven out of eight eyes experienced improved visual acuity post-surgery.
- One eye did not benefit due to optic nerve atrophy; another showed prolonged inflammation after phacoemulsification.
- No recurrence of ABD was observed in any patient during the follow-up period.
Conclusions:
- Systemic interferon-alpha is an effective therapy for ocular Adamantiades-Behçet's disease, supporting safe intraocular surgical interventions.
- The combination therapy demonstrated a low rate of inflammatory recurrence (one of eight eyes) during and after surgery.
- Interferon-alpha facilitates reliable surgical outcomes for ocular complications in ABD.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...